Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 NEW YORK and BORDENTOWN, N.J., Oct. 06, 2021 ...
November 01, 2017 09:05 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company focused on developing treatments for rare and life-threatening...